

TFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Combadiere et al.

Application No. 10/700,313 **Filed:** October 31, 2003

Confirmation No. 5461

For: CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND

THERAPEUTIC AGENTS FOR HIV

INFECTION

Examiner:

Art Unit: 1616

Attorney Reference No. 4239-66645-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 23313-1450 on the date shown below.

Attorney

for Applicant(s)

Tanya M. Harding

_ _

Date Mailed April 8, 2005

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 are two English-language documents.

Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants are filing this Information Disclosure Statement ("IDS") before the mailing of a first Office action on the merits. It is believed that no fee is due to file this IDS. If the Commissioner determines that a fee is due, Deposit Account authority is provided on the accompanying transmittal letter.

TMH:dv 04/08/05 4239-66645-01 PATENT

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding/Ph.D. Registration No. 42,630

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446

| | | | 7 |
|--------|----------|---------------|-------------------|
| TMH:dv | 04/08/05 | 4239-66645-01 | E ve |
| | | | ري . مرود عالم |

INFORMATION DISCESSURE STATEMENT BY APPLICANT

| Attorney Docket Number | 4239-66645-01 | | |
|------------------------|------------------|--|--|
| Application Number | 10/700,313 | | |
| Filing Date | October 31, 2003 | | |
| First Named Inventor | Combadiere | | |
| Art Unit | 1616 | | |
| Examiner Name | | | |

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

| Examiner's Initials* | Cite No. (optional) | Number | | Publication Date | | Name | Name of Applicant or Patentee | |
|-------------------------|------------------------|-----------|----------------------|------------------|-----------------|------------|----------------------------------|--|
| | | 5,939,320 | | Aug. 17, 19 | 999 | Littman et | al. | |
| | | | · - · · · | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | F | OREIC | SN PATENT | Γ DOCU M | IENTS | | |
| Examiner's Initials* | Cite No. (optional) | Country | | Number | Publica | tion Date | Name of Applicant or Patentee | |

| Examiner's Initials* | Cite No. (optional) | | | | 3 |
|-------------------------|------------------------|--|--|--|---|
| | | Deng et al., "Identification of a major co-receptor for primary isolates of HIV-1," Nature 381:661-666 (June 20, 1998) | | | |
| | | | | | |

| EXAMINER | DATE |
|------------|-------------|
| SIGNATURE: | CONSIDERED: |
| | |

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Combadiere et al.

Application No. 10/700,313 Filed: October 31, 2003 Confirmation No. 5461

For: CC CHEMOKINE RECEPTOR 5 DNA,

NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV

INFECTION

Examiner:

Art Unit: 1616

Attorney Reference No. 4239-66645-01

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDB

date shown below.

Attorney for Applicant(

_

Date Mailed April 8.

fanya M. Harding,

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

☐ Information Disclosure Statement ☐ Form 1449 and one reference cited thereon

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed. Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D. Registration No. 42,630

One World Trade Center, Suite 1600 121 S.W. Salmon Street

Portland, Oregon 97204 Telephone: (503) 226-7391 Facsimile: (503) 228-9446

cc:

Docketing